NCT05438394View on ClinicalTrials.gov

Clinical Study of Safety and Tolerability of Melphalan Hydrochloride for R/R MM

PHASE1UnknownINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 13, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Multiple Myeloma
Interventions
DRUG

melphalan hydrochloride for injection

Intravenous (iv) infusion for 20 minutes on Day 1 of a 21-day chemotherapy cycle

Trial Locations (1)

100044

RECRUITING

Peking University People's Hospital, Beijing

Sponsors
All Listed Sponsors
collaborator

CASI Pharmaceuticals, Inc.

INDUSTRY

lead

Peking University People's Hospital

OTHER